P16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: Correlation with outcomes following chemo-radiotherapy

Radiotherapy and Oncology

Volumn 109, Issue 1, 2013, Pages 146-151

  Gilbert, Duncan C ^a,c   Williams, Anthony ^b   Allan, Kimberley ^b   Stokoe, Joanna ^a   Jackson, Tim ^c   Linsdall, Suzanne ^c   Bailey, Charles Mh ^d   Summers, Jeff ^d  

^a Worthing Hospital   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST   (United Kingdom)

Author keywords

Anal cancer; Chemo radiotherapy; Hpv; Kras; P16ink4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; MITOMYCIN; PROTEIN P53; KRAS PROTEIN, HUMAN; ONCOPROTEIN; P16 PROTEIN, HUMAN; RAS PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ANUS CANCER; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; ANUS TUMOR; CHEMISTRY; CHEMO-RADIOTHERAPY; GENETICS; KRAS; MIDDLE AGED; MORTALITY; MUTATION; P16(INK4A); PATHOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; WART VIRUS;

ANAL CANCER; CHEMO-RADIOTHERAPY; HPV; KRAS; P16(INK4A);

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84888036454     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.08.002     Document Type: Article

References (35)

1. L.A. Eberly, C. Wiggins, and I. Nir Incidence rates for anal cancer in the United States: 1980-2009 J Clin Oncol 30 2012 (Suppl. 34; abstr. 357)
2. L.L. Gunderson, K.A. Winter, and J.A. Ajani Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/ mitomycin versus fluorouracil/cisplatin J Clin Oncol 30 2012 4344 4351
3. R. James, R. Glynne-Jones, and H. Meadows Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial Lancet Oncol 14 2013 516 524
4. D.E. Schiller, B.J. Cummings, and S. Rai Outcomes of salvage surgery for squamous cell carcinoma of the anal canal Ann Surg Oncol 14 2007 2780 2789
5. H. Zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat Rev Cancer 2 2002 342 350
6. A.K. Chaturvedi, E.A. Engels, and R.M. Pfeiffer Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 29 2011 4294 4301
7. S. Heath, V. Willis, and K. Allan Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice Clin Oncol (R Coll Radiol) 24 2011 e18 e23
8. A.G. Schache, T. Liloglou, and J.M. Risk Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination Clin Cancer Res 17 2011 6262 6271
9. P. Lassen, J.G. Eriksen, and S. Hamilton-Dutoit Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1992 1998
10. H.Y. Yhim, N.R. Lee, and E.K. Song The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy Int J Cancer 129 2011 1752 1760
11. O. Bruland, O. Fluge, and H. Immervoll Gene expression reveals two distinct groups of anal carcinomas with clinical implications Br J Cancer 98 2008 1264 1273
12. C.A. Moody, and L.A. Laimins Human papillomavirus oncoproteins: pathways to transformation Nat Rev Cancer 10 2010 550 560
13. C.B. Lajer, E. Garnaes, and L. Friis-Hansen The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer Br J Cancer 106 2012 1526 1534
14. W.H. Westra, J.M. Taube, and M.L. Poeta Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck Clin Cancer Res 14 2008 366 369
15. C.P. Neal, G. Garcea, and H. Doucas Molecular prognostic markers in resectable colorectal liver metastases: a systematic review Eur J Cancer 42 2006 1728 1743
16. A.S. Allal, L. Waelchli, and M.A. Brundler Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma Clin Cancer Res 9 2003 6489 6496
17. S. Mawdsley, H. Meadows, and R. James The role of biological molecular markers in predicting both response to treatment and clinical outcome in squamous cell carcinoma of the anus J Clin Oncol 2004 (Suppl.; GI Cancers Symp; abstr. 183)
18. C.S. Wong, M.S. Tsao, and V. Sharma Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal Int J Radiat Oncol Biol Phys 45 1999 309 314
19. T. Lampejo, D. Kavanagh, and J. Clark Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review Br J Cancer 103 2010 1858 1869
20. C.S. Kong, B. Narasimhan, and H. Cao The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas Int J Radiat Oncol Biol Phys 74 2009 553 561
21. E. Stankiewicz, D.M. Prowse, and M. Ng Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas PLoS One 6 2012 e17517
22. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
23. C.G. Hobbs, J.A. Sterne, and M. Bailey Human papillomavirus and head and neck cancer: a systematic review and meta-analysis Clin Otolaryngol 31 2006 259 266
24. N. Stransky, A.M. Egloff, and A.D. Tward The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
25. R. Glynne-Jones, D. Sebag-Montefiore, and R. Adams Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I) Cancer 119 2013 748 755
26. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
27. N. Lukan, P. Strobel, and A. Willer Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status Oncology 77 2009 293 299
28. N. Van Damme, P. Deron, and N. Van Roy Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas BMC Cancer 10 2010 189
29. M.G. Zampino, E. Magni, A. Sonzogni, and G. Renne K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol 65 2009 197 199
30. A. Paliga, R. Onerheim, and A. Gologan EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer 107 2012 1864 1868
31. E. Deutsch, C. Lemanski, and E. Paris Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16 J Clin Oncol 29 2011 (Suppl.; abstr. 4098)
32. B.C. van der Wal, B.I. Cleffken, and B. Gulec Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy J Gastrointest Surg 5 2001 383 387
33. D. Harris, J. Williamson, and M. Davies Outcome of salvage surgery for anal squamous cell carcinoma Colorectal Dis 2013 10.1111/codi.12222 [Epub ahead of print]
34. D.C. Gilbert, R. Simcock, and A. Schache Epidermal growth factor receptor and the changing face of oropharyngeal cancer J Clin Oncol 30 2012 890 891 author reply 891-892
35. J.B. Vermorken, J. Stöhlmacher-Williams, and I. Davidenko Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Lancet Oncol 14 2013 697 710